ESR1 and inflammatory breast carcinoma: This result was in contrast to those of previous studies showing that the ER+/HER2− subtype demonstrated significantly worse survival outcome compared with ER+/HER2+ or ER-negative (ER−)/HER2+ subtypes [7], or that ER positivity had a significant association with better survival outcome in patients with IBC, regardless of the type of treatment [6].